Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Rhea-AI Summary

Aethlon Medical (Nasdaq:AEMD) priced a $4.0 million follow-on offering of 5,633,009 common shares (or pre-funded warrants) plus warrants to purchase 5,633,009 shares at $0.7101 per share and warrant, at-the-market under Nasdaq rules.

Warrants become exercisable upon stockholder approval and expire five years later. Closing is expected around July 7, 2026, with net proceeds earmarked for R&D, clinical trials, capital spending and working capital.

Positive

• Follow-on offering expected to raise approximately $4.0 million gross proceeds
• Issuance of 5,633,009 shares with matching number of warrants
• Combined offering price and warrant exercise price set at $0.7101
• Proceeds allocated to R&D, clinical trials, capex and working capital

Negative

• New issuance of 5,633,009 shares implies potential shareholder dilution
• Additional 5,633,009 warrants create future equity overhang if exercised
• Warrant exercisability and term depend on stockholder approval
• Closing remains subject to customary conditions and is not yet completed

Market reaction after at-the-market follow-on offering: AEMD +11.25% in the Jul 6 session

+11.25%

6 alerts

+11.25% Session close to close

+8.0% Peak Tracked

-31.9% Trough Tracked

$1.68M Market Cap

1.3x Rel. Volume

In the Jul 6 session, AEMD gained 11.25%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.0% during that session. Argus tracked a trough of -31.9% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +11.3% in the session following this news. If shares reacted strongly higher, it wo...

Analysis

The stock surged +11.3% in the session following this news. If shares reacted strongly higher, it would contrast with the prior offering, which saw about a -45.62% move. A positive response would suggest investors view this financing as de-risking, though future capital needs could still pressure sentiment.

Key Figures

Shares offered: 5,633,009 shares Warrants offered: 5,633,009 warrants Offering price: $0.7101 per share +5 more

8 metrics

Shares offered 5,633,009 shares Follow-on offering size

Warrants offered 5,633,009 warrants Warrants to purchase common stock

Offering price $0.7101 per share Combined public offering price per share and accompanying warrant

Warrant exercise price $0.7101 per share Exercise price of common stock warrants

Gross proceeds $4.0 million Expected gross proceeds before fees and expenses

Warrant term 5 years Expiration after stockholder approval date

Closing date July 7, 2026 Expected closing of the offering

Form S-1 file number 333-296933 Effective registration statement for the securities

Previous Offering Reports

1 past event · Latest: Sep 04 (Negative)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 04	Equity offering pricing	Negative	-45.6%	Public offering of common stock and warrants totaling $4.5 million at $0.90.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior offering news was followed by a very sharp single-day decline, highlighting investor sensitivity to dilution.

Key Terms

follow-on offering, pre-funded warrants, at-the-market, registration statement on form s-1, +1 more

5 terms

follow-on offering financial

"announced the pricing of its follow-on offering of 5,633,009 shares"

A follow-on offering is when a company sells additional shares to the public after its initial stock listing to raise more cash. For investors it matters because the new shares increase the total number of shares outstanding, which can reduce each existing shareholder’s ownership share and earnings per share—similar to baking more loaves of bread after the first batch, which means each slice represents a slightly smaller piece of the whole; the funds raised can also support growth or pay debt.

pre-funded warrants financial

"shares of its common stock (or pre-funded warrants in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

at-the-market financial

"at a combined public offering price of $0.7101 per share ... priced at-the-market under applicable Nasdaq rules"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

registration statement on form s-1 regulatory

"offered pursuant to a registration statement on Form S-1, as filed"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering is being made only by means of a prospectus which forms a part"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, July 6, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of its follow-on offering of 5,633,009 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 5,633,009 shares of its common stock at a combined public offering price of $0.7101 per share (or pre-funded warrant) and accompanying warrant, priced at-the-market under applicable Nasdaq rules. The warrants will have an exercise price of $0.7101 per share, will be exercisable upon the date of stockholder approval, and will expire on the five-year anniversary from the date of stockholder approval. The shares of common stock (or pre-funded warrants) and warrants are immediately separable and will be issued separately in this offering. The closing of the offering is expected to occur on or about July 7, 2026, subject to the satisfaction or waiver of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent for the offering.

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $4.0 million. The Company intends to use the net proceeds from this offering for general corporate purposes which will include research and development expenses, clinical trial expenses, capital expenditures and working capital. The Company may also use a portion of the proceeds to in-license, acquire or invest in complimentary businesses, technologies, products or assets.

The securities described above are being offered pursuant to a registration statement on Form S-1, as filed (File No. 333-296933) as amended, which was declared effective by the Securities and Exchange Commission (the "SEC") on July 6, 2026. The offering is being made only by means of a prospectus which forms a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at www.sec.gov and may also be obtained by contacting Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device that is designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses, and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," or similar expressions constitute forward-looking statements. Such forward looking statements include but are not limited to statements regarding the expected closing of the offering, the anticipated gross and net proceeds, the intended use of proceeds, the timing of stockholder approval, and the exercisability of the warrants. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's use of net proceeds from the offering, whether the conditions to closing the offering will be satisfied, the Company's ability to obtain the requisite stockholder approval, changes in market or other conditions, the Company's ability to use the proceeds as currently anticipated, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. The preclinical findings described herein are preliminary in nature and may not be replicated in subsequent studies or clinical trials.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-pricing-of-4-0-million-follow-on-offering-priced-at-the-market-under-nasdaq-rules-302818046.html

SOURCE Aethlon Medical, Inc.

FAQ

What did Aethlon Medical (AEMD) announce in its July 6, 2026 follow-on offering?

Aethlon Medical announced pricing of a follow-on offering raising about $4.0 million. According to Aethlon Medical, the deal includes 5,633,009 common shares or pre-funded warrants plus equal warrants, all priced at a combined $0.7101, under Nasdaq at-the-market rules.

How many shares and warrants are included in Aethlon Medical’s (AEMD) $4.0 million offering?

The offering includes 5,633,009 common shares or pre-funded warrants and 5,633,009 accompanying warrants. According to Aethlon Medical, each unit is priced at a combined $0.7101, with warrants exercisable for one share each, subject to stockholder approval before exercise.

What is the exercise price and term of the Aethlon Medical (AEMD) warrants from July 2026?

The warrants carry an exercise price of $0.7101 per share. According to Aethlon Medical, they become exercisable on the date of stockholder approval and expire on the five-year anniversary of that approval, giving a defined exercise window for participating investors.

When is the Aethlon Medical (AEMD) July 2026 follow-on offering expected to close?

The offering is expected to close on or about July 7, 2026. According to Aethlon Medical, completion depends on satisfaction or waiver of customary closing conditions, meaning timing could vary slightly if standard requirements are not met promptly.

How will Aethlon Medical (AEMD) use the proceeds from the $4.0 million follow-on offering?

Net proceeds will fund general corporate purposes, including R&D and clinical trials. According to Aethlon Medical, funds may also support capital expenditures, working capital, and potentially in-licensing, acquiring, or investing in complementary businesses, technologies, products, or assets.

Who is acting as placement agent for Aethlon Medical’s (AEMD) July 2026 offering?

Maxim Group is serving as sole placement agent for the transaction. According to Aethlon Medical, Maxim Group LLC is handling placement activities, and investors will access the final prospectus through the SEC’s website or directly from the placement agent once available.